ImmunityBio (IBRX) is trading higher as investors react to the company’s April 6, 2026 disclosure that it submitted a comprehensive response to the FDA Warning Letter related to promotional communications for ANKTIVA. The move is being treated as a de-risking event after the Warning Letter and related headline risk weighed on sentiment and volatility in late March.

The FDA Warning Letter created an overhang by raising the prospect of extended scrutiny around marketing practices and compliance, which can spill over into commercial execution and payer/physician confidence even when a product remains on the market. By submitting its response, ImmunityBio is signaling active remediation and engagement with regulators, which can help narrow the range of negative outcomes investors were pricing in.

The key near-term question is whether the FDA accepts the company’s corrective actions and closes out the matter without additional enforcement steps. Traders will also watch for any follow-on company updates, changes to promotional strategy, and indicators that ANKTIVA demand and ordering trends remain resilient despite the regulatory spotlight.

Even with today’s bounce, regulatory correspondence can remain a headline risk until the FDA is satisfied and the issue is fully resolved. Separately, lawsuit-related reminders have continued to circulate in recent days, which can add noise and keep volatility elevated while the market focuses on compliance milestones and commercial performance.